Slide 1: Year End Report 2020
Year End Report 2020 “Intense work to support Health Care and Pharma Companies” Mattias Perjos, President and CEO Lars Sandström, CFO January 28, 2021
Slide 2: Getinge Year End Report 2020 January 28, 2021 Page 2
Getinge Year End Report 2020 January 28, 2021 Page 2
Slide 3: Key takeaways – performance
Key takeaways – performance Q4 2020 • Strong organic sales and order growth • Improved margins • Strengthened Free Cash Flow • Leverage improved to 1.0x (2.5x) • Dividend (proposal): 3.00 SEK/Share (1.50) 19.2 29,819 53.2 25,000 50 12 0 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q4 Q1 Q2
Slide 4: Order intake Q1-Q4 2020
Order intake Q1-Q4 2020 Trends are converging (except for Sterile Transfer, where orders grow strongly) Critical Care and Decisions to ramp up capacity in advance ICU- ventilators and ECMO Cardiopulmonary The 26,000 advanced ICU-ventilator (~50% of sales in Acute Care capacity for 2020 was fully
Slide 5: Expected net sales trends 2021 in relation to 2019
Expected net sales trends 2021 in relation to 2019 A muted H1 followed by an intense H2 Cardiopulmonary High demand on products for ECMO therapies expected to continue and capacity expected to increase incrementally throughout the year Critical Care Net sales in Critical Care is expected to be i
Slide 6: Underlying EBITA-margin improvement
Underlying EBITA-margin improvement Approx 1 pp annual improvement EBITA and underlying margin trend Earnings from additional sales related to COVID-19 Underlying EBITA-margin improvement approx. 1 pp/year 2018 2019 2020 Underlying adj EBITA, margin Adj EBITA MSEK Getinge Year End Report 2020 Januar
Slide 7: Outlook 2021
Outlook 2021 Net sales is expected to be at least 27 BSEK Long term we expect 2-4% organic annual growth in net sales Getinge Year End Report 2020 January 28, 2021 Page 7
Slide 8: Key activities and events
Key activities and events Q4 2020 Product news Improvement journey continues • Solsus 66, a versatile and cost efficient sterilizer • Enabling productivity gains in production, • A new Tegris OR platform for safe and effective logistics and OPEX workflows in the Operating Room - Decision to establis
Slide 9: Growth in net sales and orders in Q4
Growth in net sales and orders in Q4 Products for vaccine production and ECMO therapies key drivers behind order growth Global Americas EMEA APAC Order Growth +6.1% Net Sales Growth +11.1% (Organic) Getinge Year End Report 2020 January 28, 2021 Page 9
Slide 10: Order Intake per business area
Order Intake per business area Bridge Q4 2019 - Q4 2020 Organic change +3.7% +70.5% -7.1% +6.1% 571 -292 -336 MSEK 7,194 7,137 Q4 2019 Acute Care Therapies Life Science Surgical Workflows Q4 2020 The figures in tables and charts in Getinge's financial statements are no longer rounded (as was done in
Slide 11: Net Sales per business area
Net Sales per business area Bridge Q4 2019 - Q4 2020 Organic change +35.5% -12.3% -14.9% +11.1% 1,052 -59 - 699 Currency impact, MSEK -652 21.9 Organic growth, % 8,498 8,839 MSEK Q4 2019 Acute Care Life Science Surgical Q4 2020 -0.8 Therapies Workflows Capital Consumables The figures in tables and c
Slide 12: Adjusted Gross Profit and Margin development Q4 2020
Adjusted Gross Profit and Margin development Q4 2020 Bridge Q4 2019 - Q4 2020 Adj GM, % Q4 2020 59.8 39.7 38.4 51.5 (Q4 2019) (61.3) (38.5) (39.8) (50.6) 563 -13 Gross Margin impact -298 Volume Product mix 4,304 4,556 MSEK Under absorption (capital equipment) Currency Q4 2019 Acute Care Life Science
Slide 13: Financial development
Financial development Getinge Year End Report 2020 January 28, 2021 Page 13
Slide 14: Adjusted EBITA
Adjusted EBITA Bridge Q4 2019 – Q4 2020 20.6% Margin improvement +2.1 pp GP +1.4 pp OPEX 19.7% +0.0 pp Depreciation +144 -2.6 pp Currency -18 -35 89 -117 -27 FX effects amounted to 252 -394 MSEK Whereof approx. -100 MSEK related to Balance Sheet MSEK revaluation 1,817 1,673 In addition, EBITA is neg
Slide 15: Improved free cash flow, working capital and increasing ROIC
Improved free cash flow, working capital and increasing ROIC Continued efficiency enhancements Improved Free Cash Flow Improvement of WC days Improved Return on Invested Capital +864 MSEK 135 -32 days 130 125 19.0% 120 115 110 2,283 105 1,567 100 1,419 7.5% 1,368 95 988 5 0 Q2 2018 Q2 2019 Q2 2020 Q
Slide 16: Strong funding and cash position
Strong funding and cash position Improved net debt … … and leverage 14.1 3.1x 6.1 BSEK 7.5 in cash (Dec 31) 1.0 (0.6x excluding pension liabilities) 19-Sep 20-Sep 19-Dec 20-Mar 20-Jun 20-Dec 19-Sep 20-Sep 20-Mar 20-Jun 19-Dec 20-Dec Net debt, BSEK Net debt/Adj EBITDA R12 The figures in tables and ch
Slide 17: Summary
Summary Getinge Year End Report 2020 January 28, 2021 Page 17
Slide 18: Key takeaways
Key takeaways Summary Q4 2020 • Growth in organic net sales and order intake • Improved margins • Strengthened Free Cash Flow • Leverage improved to 1.0x (2.5x) • The intense cooperation with hospitals continues Getinge Year End Report 2020 January 28, 2021 Page 18
Slide 19: Q&A
Q&A Getinge Year End Report 2020 January 28, 2021 Page 19
Slide 20: Thank you
Thank you Getinge Year End Report 2020 January 28, 2021 Page 20
Slide 21: Forward looking information
Forward looking information This document contains forward-looking information based on the current expectations of the Getinge’s management. Although management deems that the expectations presented by such forward-looking information are reasonable, no guarantee can be given that these expectation
Slide 22: GETINGE
Se a GETINGE PASSION FOR LIFE